Verona Pharma plc Verona Pharma To Announce Financial Results For Full Year Ended December 31, 2018 And Provide Clinical Deve...

 
TIDMVRP 
 
   LONDON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that it will report its audited 
financial results for the full year ended December 31, 2018 on Tuesday, 
February 26, 2019. 
 
   Verona Pharma will host an investment community conference call at 8:00 
a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesday, 
February 26, 2019 to discuss the full year financial results and provide 
a clinical development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 9591328 and dialing the following numbers: 
 
 
   -- (866) 940-4574 or (409) 216-0615 for callers in the United States 
 
   -- 0800 917 4860 or 44 (0) 203 107 0297 for callers in the United Kingdom 
 
   -- 0800 180 0658 or 49 (0) 69 2222 4703 for calls in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at 
https://www.globenewswire.com/Tracker?data=XJ_MARB6QEa1Q2x8Pgbjb244wWsfrydkiSQhmYjAcODGH9t_W0z3Kk0JfbW4bmK_iOV9azfYsVAnYSZ6Jsfo1uJu4OfQ6tki3o3EmKuXS7Q= 
www.veronapharma.com and clicking on the "Events and presentations" 
link. 
 
   A webcast replay of the conference call (audio) will be available for 30 
days on the "Investors" page of Verona Pharma's website at 
www.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine, is an investigational 
first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 
3 and 4 that is designed to act as both a bronchodilator and an 
anti-inflammatory agent in a single compound. In previous clinical 
trials, the nebulized formulation of ensifentrine has been observed to 
result in bronchodilator effects when used alone or as an add-on 
treatment to other COPD bronchodilators. It has shown clinically 
meaningful and statistically significant improvements in lung function 
when administered in addition to frequently used short- and long-acting 
bronchodilators, such as tiotropium (Spiriva(R) ), compared with such 
bronchodilators administered as a single agent. Ensifentrine improved 
FEV(1) over four weeks in patients with moderate-to-severe COPD when 
compared to placebo and improved COPD symptoms and quality of life in a 
Phase 2b multicenter European study performed in 403 patients. In 
addition, ensifentrine has shown anti-inflammatory effects in a standard 
challenge study with COPD-like inflammation in human subjects. 
Ensifentrine has been well tolerated in these studies, having been 
administered to more than 800 subjects in 13 clinical trials. Verona 
Pharma is developing ensifentrine for the treatment of COPD, CF, and 
asthma. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, statements that there is an opportunity 
for additional bronchodilator and symptomatic improvement via the novel 
mechanism of action of ensifentrine and Verona Pharma's plans to carry 
out further long-term clinical studies of ensifentrine as an add-on to 
both single and dual bronchodilator therapy and the expectation that 
even more profound anti-inflammatory effects, leading to improvements in 
lung function, as well as improvements in symptoms will result. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of RPL554, which 
may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of RPL554, our only product candidate under 
development; economic, political, regulatory and other risks involved 
with international operations; the lengthy and expensive process of 
clinical drug development, which has an uncertain outcome; serious 
adverse, undesirable or unacceptable side effects associated with 
RPL554, which could adversely affect our ability to develop or 
commercialize RPL554; potential delays in enrolling patients, which 
could adversely affect our research and development efforts; we may not 
be successful in developing RPL554 for multiple indications; our ability 
to obtain approval for and commercialize RPL554 in multiple major 
pharmaceutical markets; misconduct or other improper activities by our 
employees, consultants, principal investigators, and third-party service 
providers; material differences between our "top-line" data and final 
data; our reliance on third parties, including clinical investigators, 
manufacturers and suppliers, and the risks related to these parties' 
ability to successfully develop and commercialize RPL554; and lawsuits 
related to patents covering RPL554 and the potential for our patents to 
be found invalid or unenforceable. These and other important factors 
under the caption "Risk Factors" in our Annual Report on Form 20-F filed 
with the Securities and Exchange Commission ("SEC") on February 27, 
2018, and our other reports filed with the SEC, could cause actual 
results to differ materially from those indicated by the forward-looking 
statements made in this press release. Any such forward-looking 
statements represent management's estimates as of the date of this press 
release. While we may elect to update such forward-looking statements at 
some point in the future, we disclaim any obligation to do so, even if 
subsequent events cause our views to change. These forward-looking 
statements should not be relied upon as representing our views as of any 
date subsequent to the date of this press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: +44 (0)20 3727 1000 
Simon Conway / Natalie Garland-Collins             veronapharma@fticonsulting.com 
 
ICR, Inc. (US Media and Investor enquiries) 
Darcie Robinson                                    Tel: +1 203-919-7905 
                                                    Darcie.Robinson@icrinc.com 
Stephanie Carrington                               Tel. +1 646-277-1282 
                                                    Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
February 20, 2019 02:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024